HomeWorldJapan approves OTC ‘morning-after’ pill for first time, widening access to emergency contraception

Japan approves OTC ‘morning-after’ pill for first time, widening access to emergency contraception

The approval means women and girls in Japan will now be able to buy the “morning-after” pill without a doctor’s prescription, a change long demanded by women’s rights groups.

October 22, 2025 / 02:27 IST
Story continues below Advertisement
Japan for the first time has approved what is known as the ‘morning-after’ pill without a prescription.
Japan for the first time has approved what is known as the ‘morning-after’ pill without a prescription. (representative image)

Japan has taken a landmark step in women’s health policy by approving the emergency contraceptive pill Norlevo for over-the-counter sale, the first time such a move has been made in the socially conservative country. The approval means women and girls in Japan will now be able to buy the “morning-after” pill without a doctor’s prescription, a change long demanded by women’s rights groups.

The move, announced by ASKA Pharmaceutical and confirmed by Japan’s Ministry of Health, Labour and Welfare, brings Japan in line with more than 90 countries that already allow non-prescription access to emergency contraception, according to a report by Medical Xpress.

Story continues below Advertisement

What is the morning-after pill?
The “morning-after” pill is a form of emergency contraception that prevents unwanted pregnancy after unprotected sex or contraceptive failure, such as a broken condom or missed birth-control pill. It can also be used in cases of sexual assault. The pill works by delaying ovulation and is most effective when taken as soon as possible after intercourse — ideally within 24 hours, but up to 72 hours later. It does not terminate an existing pregnancy. Common side effects include nausea, dizziness, fatigue, breast tenderness and irregular menstrual bleeding.

According to ASKA Pharmaceutical, the company received manufacturing and marketing approval from Japan’s health ministry to sell Norlevo as a “medicine requiring guidance.” This means that women must take the pill in the presence of a pharmacist, but there will be no age restrictions or requirement for parental consent. While no firm launch date has been announced, the pill is expected to reach pharmacies within this fiscal year. During a pilot in 2023, ASKA sold the pill at 145 pharmacies — less than 0.2 per cent of all pharmacies in Japan — at prices ranging between $47 and $60 (Rs 4,136–Rs 5,280), according to The Straits Times.

Why Japan’s decision marks a turning point